Botulinum toxin type A for the treatment of trigeminal neuralgia: Results from a randomized, double-blind, placebo-controlled trial

Cephalalgia

Volumn 32, Issue 6, 2012, Pages 443-450

  Wu, Chuan Jie ^a   Lian, Ya Jun ^a   Zheng, Ya Ke ^a   Zhang, Hai Feng ^a   Chen, Yuan ^a   Xie, Nan Chang ^a   Wang, Li Jun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

acute treatment; Botulinum toxin type A; double blind; placebo controlled; trigeminal neuralgia

Indexed keywords

BOTULINUM TOXIN A; CARBAMAZEPINE; GABAPENTIN; OPIATE; PLACEBO; PREGABALIN; SODIUM CHLORIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FACE ASYMMETRY; FACE EDEMA; FEMALE; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; SUBMUCOSA; TREATMENT RESPONSE; TRIGEMINUS NEURALGIA; VISUAL ANALOG SCALE;

ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXINS, TYPE A; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PAIN MEASUREMENT; TREATMENT OUTCOME; TRIGEMINAL NEURALGIA;

EID: 84861800887     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102412441721     Document Type: Article

References (29)

1. Dieleman JP, Kerklaan J, Huygen FJ, et al. Incidence rates and treatment of neuropathic pain conditions in the general population. Pain. 2008 ; 137: 681-688
2. Hall GC, Carroll D, Parry D, et al. Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain. 2006 ; 122: 156-162
3. Katusic S, Beard CM, Bergstralh E, et al. Incidence and clinical features of trigeminal neuralgia, Rochester, Minnesota, 1945-1984. Ann Neurol. 1990 ; 27: 89-95 (Pubitemid 20031363)
4. Setler PE. Therapeutic use of botulinum toxins: background and history. Clin J Pain. 2002 ; 18: S119 - S124
5. Aurora SK, Dodick DW, Turkel CC, et al. Onabotulinumtoxin A for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010 ; 30: 793-803
6. Diener HC, Dodick DW, Aurora SK, et al. Onabotulinumtoxin A for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010 ; 30: 804-814
7. Schoenen J. Botulinum toxin in headache treatment: finally a promising path?. Cephalalgia. 2010 ; 30: 771-773
8. Micheli F, Scorticati MC, Raina G. Beneficial effects of botulinum toxin type a for patients with painful tic convulsif. Clin Neuropharmacol. 2002 ; 25: 260-262 (Pubitemid 35239483)
9. Allam N, Brasil-Neto JP, Brown G, et al. Injections of botulinum toxin type A produce pain alleviation in intractable trigeminal neuralgia. Clin J Pain. 2005 ; 21: 182-184 (Pubitemid 40280233)
10. Bohluli B, Motamedi MH, Bagheri SC, et al. Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 ; 111: 47-50
11. Ngeow WC, Nair R. Injection of botulinum toxin type A (BOTOX) into trigger zone of trigeminal neuralgia as a means to control pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 ; 109: e47 - e50
12. Piovesan EJ, Teive HG, Kowacs PA, et al. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology. 2005 ; 65: 1306-1308 (Pubitemid 41508232)
13. Türk U, Ilhan S, Alp R, et al. Botulinum toxin and intractable trigeminal neuralgia. Clin Neuropharmacol. 2005 ; 28: 161-162 (Pubitemid 41134241)
14. Zúñiga C, Díaz S, Piedimonte F, et al. Beneficial effects of botulinum toxin type A in trigeminal neuralgia. Arq Neuropsiquiatr. 2008 ; 66: 500-503
15. The International Classification of Headache Disorders, 2nd edn. Cephalalgia. 2004 ; 24: 1-160
16. Devor M, Govrin-Lippmann R, Rappaport ZH. Mechanism of trigeminal neuralgia: an ultrastructural analysis of trigeminal root specimens obtained during microvascular decompression surgery. J Neurosurg. 2002 ; 96: 532-543 (Pubitemid 34230209)
17. Jorns TP, Zakrzewska JM. Evidence-based approach to the medical management of trigeminal neuralgia. Br J Neurosurg. 2007 ; 21: 253-261 (Pubitemid 47035249)
18. Taylor JC, Brauer S, Espir MLE. Long-term treatment of trigeminal neuralgia. Postgrad Med J. 1981 ; 57: 16-18
19. Wiffen PJ, McQuay HJ and Moore RA. Carbamazepine for acute and chronic pain. Cochrane Database Syst Rev 2005; CD005451.
20. Bond AE, Zada G, Gonzalez AA, et al. Operative strategies for minimizing hearing loss and other major complications associated with microvascular decompression for trigeminal neuralgia. World Neurosurg. 2010 ; 74: 172-177
21. Garza I, Cutrer FM. Pain relief and persistence of dysautonomic features in a patient with hemicrania continua responsive to botulinum toxin type A. Cephalalgia. 2010 ; 30: 500-503
22. Moon J, Ahmed K, Garza I. Case series of sixteen patients with nummular headache. Cephalalgia. 2010 ; 30: 1527-1530
23. Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther. 2004 ; 27: 26-35 (Pubitemid 38125045)
24. Graboski CL, Gray DS, Burnham RS. Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: A randomised double blind crossover study. Pain. 2005 ; 118: 170-175 (Pubitemid 41566596)
25. Freund BJ, Schwartz M. Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A. J Pain. 2003 ; 4: 159-165 (Pubitemid 36523435)
26. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003 ; 43: S9 - S15
27. Cui M, Khanijou S, Rubino J, et al. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004 ; 107: 125-133 (Pubitemid 38058707)
28. Cutrer FM, Sandroni P, Wendelschafer-Crabb G. Botulinum toxin treatment of cephalalgia alopecia increases substance P and calcitonin gene-related peptide-containing cutaneous nerves in scalp. Cephalalgia. 2010 ; 30: 1000-1006
29. Wu C, Shen J, Chen Y, et al. Comparison of two different formulations of botulinum toxin A for the treatment of blepharospasm and hemifacial spasm. Turk Neurosurg. 2011 ; 21: 625-629